Life Sciences
Moa Technology hires new CFO and CBO to expand leadership team for further growth
Moa Technology, the agricultural biotechnology company tackling herbicide-resistant weeds that threaten the world’s food security, has announced the appointment of Rob Quinn as Chief Financial Officer (CFO) and Apostolos Klontzaris as Chief Business Officer (CBO)
OMass Therapeutics expands leadership team with Melissa Faris as Chief Business Officer
OMass Therapeutics, a biotechnology company at ARC Oxford identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, has announced the appointment of Melissa Faris as Chief Business Officer.
Oxford Nanopore and Day Zero Diagnostics to develop new bloodstream infection diagnostics
Oxford Nanopore and Day Zero Diagnostics have announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.
Breakthrough Properties holds groundbreaking events for Trinity House in Oxford
Breakthrough Properties has held groundbreaking events in October to herald the start of the construction of Trinity House by Breakthrough in one of the leading academic and innovation clusters in Oxford.
EDX Medical completes acquisition of Oxford-based Hutano Diagnostics
EDX Medical has completed the acquisition of Oxford-based Hutano Diagnostics and established a Point-of-Care Innovation team to expand and accelerate the range of Hutano Diagnostics’ new tests and their integration with EDX smartphone expertise.
Parkwalk launches new fund to invest in University of Oxford science and tech spinouts
Parkwalk has launched the University of Oxford Innovation Fund VI (UOIF VI), the sixth fund in a decade long partnership with Oxford University Innovation (OUI).
Milton Park companies secure over 7% of UK’s life sciences equity investment
New research commissioned by Milton Park reveals that £2.14 billion of equity investment was generated across 272 companies based in the science, technology and business community over the past decade.
Ellison Institute submits planning application for new facility at Oxford Science Park
The facility has been designed by Foster + Partners and is devoted to reimagining and redefining cancer treatment whilst enhancing overall human health and global health policy.
European Life Sciences sector sees city centre locations grow in demand
There are significant opportunities for investors to meet growing demand from the life sciences sector, according to the 2023 Europe Life Sciences Cluster Outlook published by JLL – a leading real estate and investment management firm.
Samsara Therapeutics expands into new R&D space at Wood Centre for Innovation
The early-stage drug discovery company with operations in Oxford and Boston is looking to increase its drug discovery and validation capabilities in key neuro disease areas.
Xerion Healthcare receives funding for innovative brain tumour treatment
The funding will help to develop a unique solution that will enhance the effect of post-surgical radiotherapy on aggressive brain tumours and reduce the chance of cancer regrowth.
Oxford researchers receive £122m funding to improve health & care for NHS patients
The funding, over the next five years, was awarded to Oxford’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).
